Physician profile
Aaron Saunders
NPI 1811280241
$3,325.31
in general payments reported to CMS, 2019-2025
34 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 79% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $140 · 2021: $265 · 2022: $402 · 2023: $254 · 2024: $215 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Food and Beverage | $738.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,836.94 | 2022-2025 | |
| Amgen INC. | $147.80 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $126.11 | 2019 | |
| Seagen INC. | $112.99 | 2019-2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $95.37 | 2023-2024 | |
| Incyte Corporation | $83.37 | 2019-2024 | Jakafi |
| Janssen Biotech, INC. | $78.32 | 2019-2023 | Erleada |
| Glaxosmithkline, LLC. | $61.37 | 2020-2022 | |
| Abbvie INC. | $57.97 | 2024 | |
| Merck Sharp & Dohme LLC | $47.84 | 2022-2023 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $42.58 | 2022 | |
| Eisai INC. | $42.18 | 2023-2024 | |
| Lilly USA, LLC | $40.29 | 2021-2023 | Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $39.71 | 2019-2021 | |
| Pfizer INC. | $38.46 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $38.45 | 2019-2023 | Ninlaro |
| Myriad Genetic Laboratories, INC. | $36.08 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $33.38 | 2019-2021 | |
| Aurobindo Pharma USA, INC. | $32.84 | 2019-2020 | |
| Emd Serono, INC. | $31.58 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.05 | 2022 | |
| Stryker Corporation | $30.80 | 2023 | Spy-Phi System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.56 | 2024 | Gilotrif |
| Immunocore Limited | $24.62 | 2024 | Kimmtrak |
| Hologic INC | $24.60 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.72 | 2022 | |
| Genentech USA, INC. | $21.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.67 | 2021 | |
| Deciphera Pharmaceuticals INC. | $19.70 | 2021 | |
| Dova Pharmaceuticals | $16.78 | 2019 | |
| Eusa Pharma (US) LLC | $16.35 | 2022 | |
| Roche Diagnostics Corporation | $14.82 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $14.34 | 2024 | Imfinzi |
| Celgene Corporation | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.